How should we treat mild and moderate-severe Crohn’s disease in 2017? A brief overview of available therapies

Winter, Rachel; Burakoff, Robert

doi:10.1080/17474124.2017.1266935

Cited by 2 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, vedolizumab has a relatively slower onset of action and takes longer to be effective. 24 More recently (in July 2017), ustekinumab was recommended by NICE (TA456) as an option for treating moderate to severe active Crohn's disease in adults who previously had an inadequate response to, lost response to or could not tolerate conventional therapy or anti-TNF alpha treatment. Ustekinumab is a monoclonal antibody to the p40 subunit of interleukin (IL)-12 and IL-23 and is also used to treat plaque psoriasis and psoriatic arthritis.…”

Section: Newer Biological Drugs In Crohn's Diseasementioning

confidence: 99%

Recommended drug therapies for inflammatory bowel disease

White¹,

Thakor²,

Goel³

2018

Prescriber

View full text Add to dashboard Cite

show abstract

Section: Newer Biological Drugs In Crohn's Diseasementioning

confidence: 99%

Recommended drug therapies for inflammatory bowel disease

White¹,

Thakor²,

Goel³

2018

Prescriber

View full text Add to dashboard Cite

show abstract

Management of Crohn’s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023

Wu,

Yen,

Wang

et al. 2024

Intest Res

View full text Add to dashboard Cite

Crohn’s disease (CD) is a chronic, fluctuating inflammatory condition that primarily affects the gastrointestinal tract. Although the incidence of CD in Taiwan is lower than that in Western countries, the severity of CD presentation appears to be similar between Asia and the West. This observation indicates the urgency for devising revised guidelines tailored to the unique reimbursement system, and patient requirements in Taiwan. The core objectives of these updated guidelines include the updated treatment choices and the integration of the treat-to-target strategy into CD management, promoting the achievement of deep remission to mitigate complications and enhance the overall quality of life. Given the diversity in disease prevalence, severity, insurance policies, and access to medical treatments in Taiwan, a customized approach is imperative for formulating these guidelines. Such tailored strategies ensure that international standards are not only adapted but also optimized to local contexts. Since the inception of its initial guidelines in 2017, the Taiwan Society of Inflammatory Bowel Disease (TSIBD) has acknowledged the importance of continuous revisions for incorporating new therapeutic options and evolving disease management practices. The latest update leverages international standards and recent research findings focused on practical implementation within the Taiwanese healthcare system.

show abstract

How should we treat mild and moderate-severe Crohn’s disease in 2017? A brief overview of available therapies

Cited by 2 publications

References 16 publications

Recommended drug therapies for inflammatory bowel disease

Recommended drug therapies for inflammatory bowel disease

Management of Crohn’s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023

Contact Info

Product

Resources

About